A randomized controlled study on the effect of anti cancer formula II on the survival period of advanced gastric cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029730

Enrollment

Unknown

Registered

2020-02-10

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

experimental group:Anti-cancer formula II

control group:western medicine treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) All cases were confirmed as stage IIIB and IV gastric cancer by pathology or cytology; (2) Aged = 60 points; (5) Indications for chemotherapy; (6) The patients who had been treated with western medicine for more than one month should not be treated with other anticancer drugs before being selected for observation; (7) The patient was informed and had good compliance;

Exclusion criteria

Exclusion criteria: (1) Failing to use the medicine as required; (2) It is unable to judge the curative effect, or the data is incomplete, which affects the judgment of curative effect; (3) Patients with severe impairment of heart, liver and kidney function; (4) Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
RECIST;Survival Time;TCM syndrome;KPS;CD;	—

Countries

China

Contacts

Public ContactYin Xiaoling

Shanghai TCM Hospital

yinxiaoling2015@163.com+86 18017122656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026